



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Vignia 22313-1450
www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/800,431		03/05/2001	Victoria Beck	00231-088002 / USSN 2545 09/22		
26161	7590	08/26/2003				
FISH & RI		SON PC	EXAMINER			
225 FRANK BOSTON, N		0		CHISM, B	CHISM, BILLY D	
				ART UNIT	PAPER NUMBER	
				1654 DATE MAILED: 08/26/2003	1/	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
	09/800,431	BECK ET AL.					
Office Action Summary	Examiner	Art Unit					
	B. Dell Chism	1654					
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address					
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).					
<u>_</u>	Invil 2002						
1) Responsive to communication(s) filed on 24 A	•						
2a) ☐ This action is FINAL. 2b) ☐ Thi 3) ☐ Since this application is in condition for allowa	s action is non-final.	resecution as to the merits is					
closed in accordance with the practice under a Disposition of Claims							
4)⊠ Claim(s) <u>1-20 and 30-39</u> is/are pending in the	application.						
4a) Of the above claim(s) is/are withdraw	• •						
5)⊠ Claim(s) <u>30-36</u> is/are allowed.							
6)⊠ Claim(s) <u>1-20 and 37-39</u> is/are rejected.							
7) Claim(s) is/are objected to.		•					
8) Claim(s) are subject to restriction and/or	election requirement.						
Application Papers							
9) The specification is objected to by the Examiner							
10) The drawing(s) filed on is/are: a) accep							
Applicant may not request that any objection to the							
11) The proposed drawing correction filed on		ved by the Examiner.					
If approved, corrected drawings are required in rep	•						
12) The oath or declaration is objected to by the Exa	aminer,						
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a)-(d) or (t).					
a) ☐ All b) ☐ Some * c) ☐ None of:	. have been seed						
1. Certified copies of the priority documents	•	am Ala					
2. Certified copies of the priority documents3. Copies of the certified copies of the priority							
 3. ☐ Copies of the certified copies of the prior application from the International Bur * See the attached detailed Office action for a list of the certified copies of the prior application from the prior application from the prior application for a list of the certified copies of the prior application from the prior	eau (PCT Rule 17.2(a)).	Ç					
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) ☐ The translation of the foreign language products. ☐ Acknowledgment is made of a claim for domestic	visional application has been rec	eived.					
Attachment(s)	- F 33 120	willed Of Tau I.					
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)					
7 inioiniauon Disolosure Statement(s) (*10-1449) Paper NO(S)	6)						

Application/Control Number: 09/800,431

Art Unit: 1654

DETAILED ACTION

This Office Action is in response to Paper No. 9, filed 25 April 2003, wherein claims 21-29 were canceled, and claims 1-20 and 30-39 are pending.

Withdrawal of Objections and Rejections

The rejections and/or objections made in the prior office action, which are not explicitly stated below, in original or modified form are withdrawn.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Applicants' arguments will be addressed to the extent that they pertain to the present grounds of rejection.

Objections

Objections to the disclosure were obviated by Applicants' response.

Objections to the claims for grammar were obviated by Applicants' response.

Claim Rejections - 35 USC § 112

1. (Maintained) Claims 1-20 remain rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for autism, does not reasonably provide enablement for the spectrum of disorders possible under the heading of pervasive development disorder (PDD). The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

For the reasons stated in the previous office action, the specification is enabled for autism only and not the full range of PDDs of which autism may be found. Thus, the amendments to claims 1 and 16 do not obviate the original objection for scope of enablement.

Application/Control Number: 09/800,431

Art Unit: 1654

2. (Maintained) Claim 11 remains rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for transdermal administration, does not reasonably provide enablement for the transdermal administration of secretin by methods of acoustic waves. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.

For the reasons stated in the previous office action, the specification is enabled for transdermal administration only. Applicants argue that the specification at page 13, line 28 to page 14, line 5 affords adequate detail for enablement for the use of acoustic waves for transdermal administration of secretin. However, Applicants' recitation of the specification, while meeting the guidelines of written description, does not obviate the enablement rejection, wherein it is not known if transdermal administration of secretin by methods of acoustic waves would be probable for any patient at any time given any concentration or any dosage or formulation. Therefore, the rejection is maintained.

- 3. (Maintained) Claims 19-20 remain rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Applicants argue an enablement issue for the claims but this is an indefinite claim to a method without comprising method steps. Therefore, the claims remain rejected.
- 4. (Necessitated by Amendment) Claim 4 is rejected for the indefinite recitation of "re" wherein the claim should read "per".

Application/Control Number: 09/800,431

Art Unit: 1654

- 5. (Necessitated by Amendment) Claims 37-39 are rejected for depending from rejected claim 11.
- 6. (Withdrawn) Rejection of claim 30 as improperly depending upon itself is withdrawn, as the inclusion of claim 30 was an error as pointed out by Applicants.
- 7. (Withdrawn) Rejection of claims 4, 8, 32 and 36 for "clinical unit (CU)" is withdrawn due to Applicants arguments.
- 8. (Withdrawn) Rejection of claims 6, 10-11 and 34 for "portion of the skin" is withdrawn due to Applicants arguments.

Nonstatutory Double Patenting

- 9. (Withdrawn) Rejection of claims 1-4, 7, 30-32 and 35, for the judicially created doctrine of obviousness-type double patenting over claims 1, 3 and 9 of US 6,020,310, is withdrawn wherein Applicants filed the required Terminal Disclaimer.
- 10. (Withdrawn) Rejection of claims 1-2, 5-10, 17, 30 and 35-36, for the judicially created doctrine of obviousness-type double patenting over claims 1-2, 5-10, 17, 30 and 33-36 of US 6,197,746, is withdrawn wherein Applicants filed the required Terminal Disclaimer.

Conclusions

Claims 30-36 are allowable.

11. Applicant's amendment necessitated any new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO

Art Unit: 1654

MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to B. Dell Chism whose telephone number is 703-306-5815. The examiner can normally be reached on 7:30 AM - 4:30 PM, Monday through Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached on 703-306-3220. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

B. Dell Chism

21 August 2003

PRIMARY EXAMINER